Pharmaceutical investment company Pharma Equity Group A/S (CPH:PEG) reported on Wednesday that its subsidiary Reponex Pharmaceuticals A/S has secured a patent in Japan for its innovative treatment method using RNX-051 to eliminate biofilms in colorectal cancer.

This is a significant milestone for Reponex, which has now obtained patent protection in both Europe and Japan.

Biofilms hinder the immune system's ability to fight cancer cells. This treatment method addresses a pressing need in the global colorectal cancer market, valued at USD9.4bn in 2020.

The patent is valid until 2039, and its protection is crucial for future licensing negotiations.

Colorectal cancer is a major public health issue in Japan, with increasing incidence and prevalence.